Drug Trial Radar · NCT07622225
SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Dec 31, 2028
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase Ib/II clinical study. It includes two stages: Phase Ib and Phase II. In the Phase Ib stage, the primary objective is to evaluate the safety and tolerability of SYS6006 in combination with Enlonstobart Injection in participants with advanced solid tumors, and to provide a basis for dose selection in later clinical studies. The primary objective of the Phase II stage is to assess efficacy and safety of SYS6006 in combination with Enlonstobart Injection in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SYS6006Biological
Drug:SYS6006 Phase Ib dose level 1: SYS6006 Intramuscular injection; dose level 2: SYS6006 Intramuscular injection
EnlonstobartBiological
Enlonstobart IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence and frequency of dose-limiting toxicities (DLTs) during the study (applicable to the combination therapy dose-escalation phase)Time frame: Within 21 days after the start of the treatment
- Phase Ib: Incidence and frequency of treatment-emergent adverse events (TEAEs) .Time frame: Through study completion, an average of l year
- Phase Ib:Incidence and frequency of serious adverse events (SAEs)Time frame: Through study completion, an average of l year
- Phase Ib:Maximum tolerated dose (MTD)Time frame: Every 21 days while on treatment (estimated 6 months)
- Phase Ib: Recommended Phase II dose (RP2D)Time frame: Every 21 days while on treatment (estimated 6 months)
- Phase II: ORR as assessed by the investigator according to RECIST v1.1Time frame: through study completion, an average of 1year.
- Phase II: Incidence and frequency of TEAEs.Time frame: through study completion, an average of l year
- Phase II:Incidence and frequency of SAEs.Time frame: through study completion, an average of l year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.